2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Immunotherapy, Non-Biological Therapies, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Genomics, Immune Mechanism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality of Care, Systems-Based Hematology, Diseases, Bleeding and Clotting, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Measurable Residual Disease, CLL, B Cell Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly
PAPER

2135 Clinical, pathological, imaging, and biological characteristics of accelerated CLL and Richter transformation

Ziyuan Zhou, Luomengjia Dai2, Dan Yang3, Hanyi Ouyang4, Wen Chen5, Chongyang Ding6, Jianyong Li, MD7, Huayuan Zhu, MD, PhD8
1 The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China
2 The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China
3 The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China
4 The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China
5 The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China
6 The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China
7 The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China
8 The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China

Aims:

Both accelerated chronic lymphocytic leukemia (aCLL) and Richter transformation as diffuse large B-cell lymphoma (RT-DLBCL) represent aggressive disease stages of CLL, associated with poor clinical outcomes. However, the differences of characteristics between aCLL and RT remain incompletely defined. This study aimed to characterize the clinical, pathological, and biological features of aCLL and RT, and explore the potential role of circulating tumor DNA (ctDNA) as a biomarker of disease burden and outcome.

Methods:

40 aCLL and 70 RT-DLBCL patients with histologically confirmed between 2014 and 2025 were retrospectively included. Clinical and biological data were analyzed, including laboratory tests, fluorescence in situ hybridization (FISH), karyotype, and immunoglobulin heavy chain variable region (IGHV) mutation status and gene usage. Additionally, pathological and 18F-FDG PET/CT features were also analyzed. Targeted next-generation sequencing (NGS) was performed using available tissue, peripheral blood (PB) /bone marrow (BM), and plasma. Progression-free survival (PFS) is defined as the time from diagnosis to first disease progression or death, or last follow-up. Overall survival (OS) is defined as the time from diagnosis to death or last follow-up.

Results:

25 (62.5%) aCLL and 60 (85.7%) RT-DLBCL patients had a prior diagnosis of CLL, respectively. Among patients previously treated, aCLL patients had a significantly longer interval from the last line treatment to disease progression (median 29.8 vs. 9.8 months, p=0.026). aCLL patients were younger and exhibited lower clinical disease burden than RT-DLBCL patients at diagnosis. Analysis of IGHV in PB/BM samples demonstrated substantial overlap between two groups, and stereotyped BCR subset #8 was identified in 4 aCLL and 8 RT-DLBCL patients. Histological evaluation demonstrated progressive morphological changes from indolent CLL to aCLL and RT-DLBCL, characterized by expansion of proliferation centers, increasing cytological transformation, and acquisition of large-cell morphology in RT-DLBCL. Immunohistochemical analysis demonstrated progressive loss of canonical CLL markers in RT-DLBCL, whereas these markers were largely retained in aCLL. Ki-67, MYC, and BCL6 expression increased across disease stages consistent with proliferative activity. SUVmax progressively increased from CLL to aCLL and RT-DLBCL (median 5.2 vs. 7.4 vs. 12.6, all p<0.05), reflecting increased focal metabolic activity. In contrast, TMTV and TLG were comparable between CLL and aCLL but markedly elevated in RT-DLBCL. Individual PET parameters showed limited ability to distinguish different disease stages, whereas integrated models incorporating SUVmax, TMTV/TLG, and extranodal involvement improved discrimination. The median OS and PFS of aCLL patients were not reached and 43.6 months, both significantly superior to RT (the median OS and PFS were 14.1 and 5.4 months). Notably, among both aCLL and RT-DLBCL cohorts, patients who developed disease progression after prior CLL-directed therapy had significantly inferior PFS and OS compared with previously untreated patients. Plasma ctDNA showed high concordance with tumor tissue sequencing, and revealed distinct molecular landscapes between aCLL and RT-DLBCL, with RT-DLBCL showing enrichment of alterations related to cell cycle, proliferation, BCR signaling, and chromatin remodeling, whereas aCLL displayed an intermediate profile. Additionally, plasma ctDNA burden was correlated with clinical and PET/CT metabolic tumor burden parameters, including TMTV and TLG. Higher ctDNA levels were associated with inferior PFS and OS, supporting its potential role as a biomarker for disease burden assessment and prognostic stratification.

Discussion:

Our findings provide an integrated characterization of aCLL and RT-DLBCL, demonstrating that aCLL represents a distinct aggressive disease stage with intermediate clinical, pathological, PET/CT metabolic, and molecular features between indolent CLL and RT-DLBCL. Compared with RT-DLBCL, aCLL exhibited lower tumor burden, preserved CLL-associated phenotypes, and less extensive genomic alterations, while showing increased proliferative activity and focal metabolic activation. Plasma ctDNA reflected aggressive genomic changes, correlated with clinical and PET/CT metabolic tumor burden and clinical outcomes, and may serve as a potential biomarker for disease monitoring and risk stratification.

Huayuan Zhu, MD, PhD: No relevant conflicts of interest to declare.